0
Home
Products
Triptorelin – (57773-63-4)
Triptorelin - (57773-63-4)

Triptorelin – (57773-63-4)

Triptorelin is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of advanced prostate cancer and central precocious puberty (CPP). It functions by binding to GnRH receptors in the pituitary gland, initially causing a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, followed by a down-regulation of these hormones. This results in a decrease in testosterone production in men and estrogen production in women, which is beneficial for managing hormone-sensitive conditions.

In the context of prostate cancer, triptorelin is used as part of androgen deprivation therapy to reduce testosterone levels, thereby slowing cancer growth. For CPP, it helps delay the onset of puberty in children who begin developing too early. Triptorelin is administered via intramuscular injection and is available in various formulations, including immediate-release and extended-release options.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

SKU: 57773-63-4
Categories: ,
Tags: , , ,

Triptorelin is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of advanced prostate cancer and central precocious puberty (CPP). It functions by binding to GnRH receptors in the pituitary gland, initially causing a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, followed by a down-regulation of these hormones. This results in a decrease in testosterone production in men and estrogen production in women, which is beneficial for managing hormone-sensitive conditions.

In the context of prostate cancer, triptorelin is used as part of androgen deprivation therapy to reduce testosterone levels, thereby slowing cancer growth. For CPP, it helps delay the onset of puberty in children who begin developing too early. Triptorelin is administered via intramuscular injection and is available in various formulations, including immediate-release and extended-release options.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Triptorelin
https://pubchem.ncbi.nlm.nih.gov/compound/25074470
https://www.medkoo.com/products/41548
https://medlineplus.gov/druginfo/meds/a611047.html#:~:text=Triptorelin
https://www.mayoclinic.org/drugs-supplements/triptorelin-intramuscular-route/description/drg-20066536
https://www.ncbi.nlm.nih.gov/books/NBK548756/
Other Names

Arvekap

IUPAC Name

(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

CAS

57773-63-4

Molecular Weight

1311.4

Molecular Formula

C64H82N18O13

SMILES

CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8

Related products

No products in the cart.